share_log

Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular Care

Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular Care

Terumo健康結果與Medis醫療影像宣佈戰略合作伙伴關係,以提升心血管護理
PR Newswire ·  12/10 21:00

– Collaboration combines Terumo's ePRISM precision medicine software platform with Medis' QFR technology –

– 合作將Terumo的ePRISm精準醫療軟件平台與Medis的QFR技術結合在一起 –

SOMERSET, N.J., Dec. 10, 2024 /PRNewswire/ -- Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), and Medis Medical Imaging, a leading cardiac imaging software company, announced today that they have entered into a strategic partnership, in the United States, to enhance cardiovascular care through the utilization of both ePRISM – Terumo's proprietary clinical decision support platform – and Medis' Quantitative Flow Ratio (QFR) technology, a non-invasive software solution designed to assess angiography-derived coronary physiology. The use of ePRISM and Medis QFR will be piloted at selected clinical sites, leveraging real-time data from electronic health records to provide prospective insights to help enhance patient care.

新澤西州薩默塞特,2024年12月10日 /PRNewswire/ -- Terumo健康結果(THO),Terumo介入系統(TIS)的一個部門,以及Medis醫療影像,一家領先的心臟影像軟件公司,今天宣佈他們在美國達成了一項戰略合作伙伴關係,以通過利用ePRISm -- Terumo的專有臨床決策支持平台 -- 和Medis的定量血流比(QFR)技術,一種旨在評估血管造影得到的冠狀動脈生理的非侵入性軟件解決方案,來增強心血管護理。ePRISm和Medis QFR的使用將在指定的臨床地點進行試點,利用電子健康記錄中的實時數據提供前瞻性洞見,以幫助改善患者護理。

THO's partnership with Netherlands-based Medis Medical Imaging represents a significant step in enhancing clinical decision support capabilities, streamlining workflows and, most importantly, improving patient outcomes by providing interventional cardiologists with precise anatomical and physiological assessments of coronary artery disease (CAD).

THO與荷蘭Medis醫療影像的合作代表着提升臨床決策支持能力的重要一步,簡化工作流程,並且最重要的是,通過爲介入性心臟病學家提供精確的冠狀動脈疾病(CAD)解剖和生理評估,改善患者結果。

More than 60 million people currently suffer from coronary artery disease (CAD) worldwide1. Percutaneous Coronary Intervention (PCI) is a common method for treatment and management of patients with CAD. As Medis QFR is an angiographic image-based approach, it eliminates the need for a more invasive wire-based approach in assessing coronary physiology. It is also capable of evaluating multiple areas from the same images versus the wire-based approach which is vessel- and often lesion-specific. This can potentially increase efficiency and safety while reducing procedure time.

目前全球有超過6000萬的人患有冠狀動脈疾病(CAD)。經皮冠狀動脈介入(PCI)是治療和管理CAD患者的常見方法。由於Medis QFR是一種基於血管造影圖像的方法,它消除了在評估冠狀動脈生理中需要更具侵入性的導絲方法的必要。它還能夠從同一圖像中評估多個區域,而不是導絲方法,它通常是針對特定血管和病變的。這可以潛在地提高效率和安全性,同時減少手術時間。

The FAVOR trials, performed in the EU, have proven the efficacy of the Medis QFR solution in practical use during and after an interventional procedure. The FAVOR III China trial demonstrated a 34% reduction in major adverse cardiac events (MACE) in a one-year follow-up of patients treated with Medis QFR-guided versus standard angiography-guided procedures, and similar results were obtained after two years2. The FAVOR Trials, which used the first-generation QFR technology, demonstrated high accuracy compared to the pressure wire. This led to Medis QFR being approved and reimbursed in Japan, and included in the 2024 ESC guidelines for chronic coronary syndromes with a Class I recommendation. The PIONEER IV trial, a 2,540-patient study, aims to evaluate the superiority of the next-generation QFR technology – for both pre- and post-procedure stenting recommendations – which will be integrated with THO's ePRISM platform.

在歐洲進行的FAVOR試驗證明了Medis QFR解決方案在介入程序期間和之後實際使用的有效性。FAVOR III中國試驗顯示,在使用Medis QFR指導的患者與使用標準血管造影指導的程序在一年的隨訪中,主要不良心臟事件(MACE)減少了34%,並且在兩年後獲得了相似的結果。FAVOR試驗使用第一代QFR技術,顯示出與壓力導絲相比的高準確性。這導致Medis QFR在日本獲得批准和報銷,並被納入2024年歐洲心臟病學會(ESC)慢性冠狀動脈綜合徵的指南中,具有I類推薦。PIONEER IV試驗,一項2540名患者的研究,旨在評估下一代QFR技術在術前和術後支架植入建議中的優越性,這將與THO的ePRISm平台集成。

"This collaboration underscores Terumo's commitment to building an innovative care operating system that not only improves clinical outcomes but also streamlines the entire care pathway," said Ryan Graver, Senior Divisional Vice President, THO. "By utilizing our ePRISM platform alongside Medis' QFR technology and TIS' devices, we are equipping clinicians with a comprehensive suite that enhances procedural efficiency and patient outcomes. Together, we are redefining what's possible in cardiovascular care."

"這次合作凸顯了Terumo在構建創新護理操作系統方面的承諾,該系統不僅改善臨床結果,還簡化了整個護理路徑," THO高級副總裁Ryan Graver表示。"通過利用我們的ePRISm平台與Medis的QFR技術和TIS的設備,我們正在爲臨床醫生提供一整套全面的解決方案,提升程序效率和患者效果。我們共同重新定義了心血管護理的可能性。"

"At Medis Medical Imaging, we are thrilled to partner with Terumo Health Outcomes to push the boundaries of cardiovascular imaging and decision support," said Maya Barley, CEO of Medis Medical Imaging. "This collaboration provides a comprehensive solution that enhances diagnostic accuracy and treatment planning. It highlights our dedication to improving patient care through innovation, working together with our worldwide network of partners."

"在Medis醫學影像公司,我們非常高興能與Terumo健康結果公司合作,推動心血管影像和決策支持的邊界," Medis醫學影像首席執行官Maya Barley表示。"這次合作提供了全面的解決方案,增強了診斷準確性和治療計劃。這凸顯了我們通過創新改善患者護理的承諾,和我們全球合作伙伴網絡共同努力。"

THO is a division of TIS, which offers a portfolio of high-quality interventional devices that complement the predictive insights offered by the ePRISM platform. While ePRISM assists clinicians in identifying patient risk and optimizing treatment strategies, the advanced tools from TIS support procedural efficiency, contributing to improved patient outcomes. This combination assists clinicians to make more informed decisions, facilitating smoother procedures and potentially reducing hospital costs and recovery times.

THO是TIS的一個部門,提供高質量介入設備的產品組合,補充了ePRISm平台提供的預測見解。雖然ePRISm幫助臨床醫生識別患者風險並優化治療策略,但TIS的先進工具支持程序效率,有助於改善患者結果。這種組合幫助臨床醫生做出更明智的決策,促進更順利的程序,並可能降低醫院成本和恢復時間。

1 Tijn P.J. Jansen et al., Assessing Microvascular Dysfunction in Angina with Unobstructed Coronary Arteries. JACC 2021.

2 Xu B., Tu S., Song L., Jin Z., Yu B., Fu G., Zhou Y., Wang J., Chen Y., Pu J., et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): A multicentre, randomised, sham-controlled trial. Lancet. 2021;398:2149–2159. doi: 10.1016/S0140-6736(21)02248-0

1 Tijn P.J. Jansen等人,在無阻塞冠狀動脈中評估微血管功能障礙。JACC 2021。

2 Xu b., Tu S., Song L., Jin Z., Yu b., Fu G., Zhou Y., Wang J., Chen Y., Pu J., 等。冠狀動脈介入的血管造影定量血流比指導(FAVOR III China):一項多中心,隨機,假手術對照試驗。柳葉刀。2021;398:2149–2159。doi: 10.1016/S0140-6736(21)02248-0

About Terumo Health Outcomes

關於Terumo健康結果

Combining best-in-class care pathway consulting services with proven, state-of-the-art ePRISM precision medicine software platform, Terumo Health Outcomes (), a division of Terumo Interventional Systems, partners with clinicians and hospitals to deliver enhanced patient outcomes and operational efficiencies. The predictive power of ePRISM allows Terumo to deliver innovative digital solutions, providing clinicians with comprehensive, predictive patient analytics and critical data to help support treatment at the point of care – ultimately lowering the cost of healthcare delivery.

將一流的護理路徑諮詢服務與經過驗證的、先進的ePRISm精準醫療軟件平台相結合,Terumo 健康成果(),作爲Terumo介入系統的一部分,與臨床醫生和醫院合作,以提供增強的患者結果和運營效率。ePRISm的預測能力使Terumo能夠提供創新的數字解決方案,爲臨床醫生提供全面、預測性的患者分析和關鍵數據,以幫助在護理點支持治療,從而最終降低醫療服務的成本。

About Terumo

關於Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for over 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large. More information can be found at .

Terumo(東京證券交易所代碼:4543)是醫療技術的全球領導者,致力於「通過醫療保健爲社會貢獻」已經超過100年。總部位於東京,業務遍及全球,Terumo在全球有超過30,000名員工,爲160多個國家和地區提供創新的醫療解決方案。該公司最初是一家日本體溫計製造商,自那時以來一直支持醫療保健。現在,它的廣泛業務組合涵蓋了血管介入、心臟外科解決方案、輸血和電芯治療技術,以及日常臨床實踐中必不可少的醫療產品,如輸血系統、糖尿病護理和腹膜透析治療。Terumo將進一步努力爲患者、醫療專業人士和整個社會創造價值。更多信息請訪問。

About Medis Medical Imaging

關於Medis醫療成像

For over 35 years, Medis has been providing innovative, robust and extensively validated tools to the medical community worldwide. The heritage and core values are based on this strong purpose of contributing to a healthier society by providing the right tools to cardiologists, radiologists, researchers, and industry partners. Medis' software is internationally appreciated due to its ease of use and its clinical outcome for the patients. At Medis, quality is key, all the products are developed and validated extensively to guarantee the highest quality, without compromise. They continuously focus on the creation of clinically relevant innovative software solutions in the cardiovascular imaging domain.

35年來,Medis一直爲全球醫療界提供創新、堅固且經過廣泛驗證的工具。它的傳統和核心價值觀基於這個強烈的目標,即通過爲心臟病專家、放射科醫生、研究人員和行業合作伙伴提供合適的工具,爲社會的健康做出貢獻。Medis的軟件因其易用性和對患者臨床結果的影響而受到國際認可。在Medis,質量是關鍵,所有產品均經過廣泛的開發和驗證,以確保最高質量,絕不妥協。他們持續專注於開發與心血管成像領域相關的臨床創新軟件解決方案。

SOURCE Terumo Medical Corporation

來源:泰爾茂醫療公司

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎?

440k+
440k+

Newsrooms &
新聞編輯室和

Influencers
意見領袖
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
已選擇加入
GET STARTED
開始

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論